JSAM
RARE icon

J. Safra Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

J. Safra Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-68
Closed -$1.56K – 659
2025
Q4 		$1.56K Hold
68
– – ﹤0.01% 602
2025
Q3 		$2.04K Buy
+68
New +$2.04K ﹤0.01% 400

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

J. Safra Asset Management's RARE Position: Q1 2026 in Review

J. Safra Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 68 shares — an estimated $1.56K sold.

J. Safra Asset Management first reported a position in RARE in Q3 2025 and held it in 2 quarters. The position peaked at $2.04K in Q3 2025. 298 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • J. Safra Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • J. Safra Asset Management sold 68 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.56K.
  • J. Safra Asset Management first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and held it in 2 quarters.
  • J. Safra Asset Management's Ultragenyx Pharmaceutical position peaked at $2.04K in Q3 2025.
  • 298 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on J. Safra Asset Management's 13F filing for Q1 2026, filed 4 May 2026.